The Association and Clinical Implications of Gastroesophgeal Reflux Disease and H. pylori
|
|
- Belinda Park
- 6 years ago
- Views:
Transcription
1 The Association and Clinical Implications of Gastroesophgeal Reflux Disease and H. pylori Maxwell M. Chait The relationship between GERD and H. pylori is complex and negatively associated with important implications for both individual patients and the nations of the world. Whereas the incidence of GERD and its complications, including Barrett s esophagus and adenocarcinoma of the esophagus and gastric cardia have increased, the incidence of H. pylori related gastroduodenal peptic ulcer disease and distal gastric adenocarcinoma has decreased in Western Europe and the United States. This suggests an inverse, negative, relationship between the two. H. pylori infection eradication does not cause GERD, but there is possibly a protective and negative effect of H. pylori in patients with GERD which is related to the virulence of the infecting strain and the distribution and severity of gastritis. It remains controversial whether or not to test and treat for the infection of H. pylori with respect to the direct management of GERD, because of its potentially protective effect. However, in patients who require long term therapy with PPI agents, a test and treat strategy may be appropriate, since PPI therapy might increase the risk of atrophic gastritis and its potential for B 12 malabsorption and gastric cancer in H. pylori infected individuals. If the prevalence of H. pylori decreases in the developing countries of the world, one may anticipate that there will be a decrease in incidence of cancer of the gastric body and antrum and an increase in the prevalence of GERD and incidence of adenocarcinoma of the esophagus and gastric cardia over the next few decades. This is an evolving area with important implications for individual patients as well as for the nations of the world. Maxwell M.Chait, M.D., F.A.C.P., F.A.C.G., Assistant Clinical Professor of Medicine, Columbia University College of Physicians and Surgeons, Hartsdale, New York. 40
2 INTRODUCTION Gastroesophageal reflux disease (GERD) is the most common upper gastrointestinal problem seen in clinical practice. It is estimated that 10% 20% of adults have symptoms at least once weekly and 15% 40% have symptoms at least once monthly (1). Complications of GERD vary from esophagitis and esophageal stricture to Barrett s esophagus and esophageal cancer. In contrast, H. pylori infection is the most common acquired factor in the etiology of gastritis and ulcers of the stomach and duodenum and in adenocarcinoma of the body and antrum of the stomach (2). Remarkably, as the prevalence of H. pylori and its complications has declined in the industrialized nations of the world, the incidence of GERD and its complications have increased, suggesting a negative association between the two disease states. H. pylori does not predispose to GERD. In fact, evidence indicates a possible protective role. But, there is a higher incidence of atrophic gastritis in patients taking proton pump inhibitor (PPI) agents with H. pylori infection. Therefore, the relationship between GERD and H. pylori is complex and may have important implications for the individual patient as well as for the nations of the world. PATHOPHYSIOLOGY OF GERD AND H. PYLORI GERD is predominantly a motility disorder. The abnormalities that appear to play a pathogenic role in GERD are a defective antireflux barrier, abnormal esophageal clearance, reduced salivary production, altered esophageal mucosal resistance, and delayed gastric emptying. Injury to the esophagus is due primarily to reflux of gastric acid and pepsin. In some cases, duodenogastric reflux of bile may cause the injury (3). Nocturnal gastroesophageal reflux is associated with more severe manifestations and esophageal and extraesophageal complications of GERD (4 6). The lower esophageal sphincter (LES) is the antireflux barrier. Abnormalities that make it dysfunctional promote acid reflux and the constellation of GERD problems. The most common cause of reflux episodes is transient LES relaxations, the drop in LES pressure not accompanied by swallowing. Multiple medications, such as nitrates, calcium channel blockers, benzodiazepines, anticholinergics, and antidepressants decrease LES pressure. The presence of a hiatal hernia impairs the function of the LES and may impair the clearance of refluxed acid from the distal esophagus (7). Reduction in esophageal acid clearance impaired by disturbances of esophageal motility and saliva production, delayed gastric emptying and duodenogastric reflux are also important factors. Although all ages are affected, the elderly tend to have more severe complications of GERD (8). GERD is also associated with the development of adenocarcinoma of the distal esophagus and gastric cardia. The pre-malignant lesion for the development of these cancers is Barrett s esophagus. H. pylori is highly associated with gastritis and gastroduodenal peptic ulcer disease. However, its effect on gastric acid depends upon the severity and distribution of gastritis within the stomach, with either increased, decreased, or unchanged gastric acid secretion. In H. pylori infection that is antrum predominant, there is hypergastrinemia, gastric hypersecretion and the propensity to gastroduodenal ulcer. All of the abnormalities resolve completely after eradication of the H. pylori organism except for the increased maximal acid output in response to gastrin which remains unchanged in these patients (9). In contrast, patients with corpus predominant infection tend to decreased gastric acid secretion which returns to normal with eradication of H. pylori. Basal gastric acid secretion is increased in subjects whose infection was eradicated, but not in those with persistent infection. However, basal and meal stimulated gastric acid secretion does not change after H. pylori eradication (10). Therefore, most studies suggest that patients with antrum predominant gastritis have increased gastric acid secretion that returns to normal after H. pylori eradication and patients with corpus predominant gastritis have reduced gastric acid secretion that returns to normal after eradication (11). Additionally, H. pylori may influence the gastric acid content of the gastric refluxate and affect patterns of gastritis and gastric acid secretion by release of ammonia by H. pylori, which may partially neutralize gastric acid (12). The amount of gastritis in the body of the stomach associated with lower gastric acidity returns to normal when H. pylori is eradicated. Also, the hypergastrinemia noted in these patients may lead to lower esophageal sphincter pressure (13). H. pylori, is associated with the development of atrophic gastritis and ade- (continued on page 45) 41
3 (continued from page 41) nocarcinoma of the body and antrum of the stomach. Atrophic gastritis is associated with B 12 malabsorption and is a pre-malignant lesion for the development of gastric cancer (2). Virulent strains of H. pylori, such as the cag A+ strain are associated with increased development of atrophic gastritis and gastric cancer (14,15). No causal relationship between H. pylori infection and gastroesophageal reflux disease has been demonstrated (16,17). However, H. pylori eradication may have a possible negative effect upon GERD. H. pylori eradication effects on the development of GERD would largely depend upon the patterns of gastritis and the disturbance of gastric acid secretion induced by the infection and could vary from individual to individual (18). For example, in patient s with H. pylori antrum predominant infection, which is associated with increased acid secretion, eradication of the infection will lower acid secretion and may improve the GERD. On the contrary, if the infection is corpus predominant, which is associated with reduced acid secretion, treatment of the infection will result in increased acid secretion which may induce or aggravate GERD. If H. pylori infection produces no overall disturbance of acid secretion, then treatment of the infection is unlikely to have an effect on GERD (19). Also, by treating H. pylori infection in a given population, the development or aggravation of GERD in that population will depend upon the pattern of H. pylori infection prevalent in that population. For example, studies from Asia, where H. pylori tends to be corpus predominant and associated with lower gastric acid secretion, show aggravation of esophagitis after H. pylori treatment (19,20). However, studies from Western Europe and the United States, where there is no regional preponderance of H. pylori infection, show conflicting results after H. pylori eradication (21,22). THE NEGATIVE RELATIONSHIP BETWEEN GERD AND H. PYLORI There is a substantial body of epidemiologic evidence that shows an inverse or negative association between the incidence of gastroesophageal reflux disease and H. pylori infection. The incidence of GERD in the industrialized countries of the Western world is quite high. For example, approximately 15% 40% of the adult U.S. population has heartburn symptoms. (1) Also, the incidence of GERD complications, especially adenocacinoma of the esophagus, is rising. In contrast the prevalence of H. pylori along with its complication of gastric adenocarcinoma is steadily decreasing in these nations. This is probably due to improvements in hygiene and socioeconomic factors and the treatment of H. pylori (23). Labenz, in a study of 6,125 patients with GERD, evaluated independent predictors of erosive disease, including male gender, increased body mass, regular alcohol intake and duration of disease. He showed that H. pylori had a protective effect in the subgroup analysis of patients with more severe Los Angeles C and D grade of esophagitis (24). Some studies have found that this negative association between H. pylori and GERD is more marked with more virulent caga+ strains of the infection. In another study, however, Kuipers did not observe a significant change in inflammation in patients with and without eradication of H. pylori in GERD patients, although there was a trend towards reduced control in the eradicated group (25). H. pylori may have a possible protective effect, especially the caga+ strain, for the development of the complications of GERD, including Barrett s esophagus and adenocarcinoma of the esophagus and gastric cardia. It is well known that complications of GERD are significantly more frequent in Caucasian rather than in African American or Asian populations, which is inversely proportional to the frequency of H. pylori infection. Several studies have reported a negative association between the prevalence of H. pylori, especially the caga+ strain, and the severe GERD complications of Barrett s esophagus and esophageal adenocarcinoma, which suggests a protective effect (26). A study from China revealed a stepwise relationship found between the increasing grade of esophagitis and decreasing prevalence of H. pylori (27). A Swedish study showed that H. pylori was associated with a significantly decreased risk of adenocarcinoma of the esophagus (27). A subgroup analysis showed that the negative association was only apparent for the caga+ strains of H. pylori (28). PROTON PUMP INHIBITORS AND H. PYLORI The most common and effective way of treating patients with GERD is by suppressing gastric acid 45
4 secretion with proton pump inhibitor (PPI) agents. The degree of inhibition of gastric acid secretion and elevation of gastric ph that are achieved by PPI agents are substantially greater in the H. pylori infected than uninfected patients and in H. pylori eradicated patients. For example, in H. pylori infected patients, Omeprazole at 20 mg per day produced a median gastric ph of 5.5. After eradication of H. pylori, the ph fell to 3.0 (29). Wu demonstrated that H. pylori eradication was the only predictor of treatment failure in patients after adjustments for age, sex, erosive esophagitis and hiatal hernia (30). Holtzman found that both the rate of healing of endoscopically proven esophagitis and the rate of resolution of symptoms was more rapid in the H. pylori infected patients treated with PPI agents, as compared to H. pylori uninfected patients (31). Two mechanisms are likely to contribute to the enhanced potency of PPI agents in the presence of H. pylori. PPI agents appear to transform the pattern of H. pylori gastritis into a corpus predominant pattern of gastritis, producing a marked increase in the inflammation in the acid secretion regions of the stomach which inhibits parietal cell function and gastric acid secretion. (32,33) This reduction of gastric acid supplements the pharmacological affect of PPI agents. In addition, ammonia produced by the H. pylori urease helps neutralize acid and thus contribute to the elevation of intragastric ph. Although both effects are probably minor, the increased efficacy of PPI agents may be associated with improved symptom control and more rapid healing of esophagitis. H. pylori infection has also been shown to affect the level of gastric acid secretion after discontinuing PPI therapy. For example, discontinuation of PPI therapy in some patients results in rebound hypersecretion of gastric acid which continues for several months in H. pylori eradicated patients. This may be the result of a trophic affect of the elevated gastrin level during H. pylori infection that exerts a prolonged effect upon the parietal cell mass. In contrast, some patients with H. pylori infection did not show a significant rebound hypersecretion. This protective effect may be explained by a corpus predominant pattern of gastritis induced by PPI agents in H. pylori infected subjects that produces a persistent inhibition of gastric acid secretion after stopping the drug and prevents rebound acid hypersecretion (34). As PPI agents change the H. pylori distribution to a corpus predominant pattern, it has been postulated that they may accelerate the development of atrophic gastritis and potentially increase the risk of gastric cancer as compared to uninfected patients. Virulent strains of H. pylori, such as caga+, have been reported to cause a greater risk of developing atrophic gastritis and gastric adenocarcinoma. Because of this potential threat of increased gastric cancer in these patients, a test and treat strategy has been proposed by the Maastricht Consensus Conference as well as by other investigators (35). However, PPI agents do not promote intestinal metaplasia (36). Thus, it remains unclear if long term use of PPI agents in H. pylori infected patients poses a significant risk for the development of gastric cancer in later life. CONCLUSION The relationship between GERD and H. pylori is complex and negatively associated with important implications for the individual and the populations of the world. The incidence of GERD and its complications, including adenocarcinoma of the esophagus, has increased in recent years, whereas the incidence of H. pylori related gastroduodenal peptic ulcer disease and distal gastric adenocarcinoma has decreased in the industrialized nations of the Western world, suggesting an inverse relationship between the two. Current data demonstrate that H. pylori infection eradication does not cause gastroesophageal reflux disease. However, there is possibly a protective and negative association between H. pylori infection, especially the more virulent caga+ strain, and the development of GERD and its complications of Barrett s esophagus and esophageal cancer that appears to depend upon the distribution and severity of the H. pylori gastritis. It remains controversial whether or not to treat for the infection of H. pylori with respect to the direct management of GERD, because of its potentially protective effect. However, in patients who require long term therapy with PPI agents, a test and treat strategy may be appropriate, since PPI therapy might increase the risk of atrophic gastritis with its potential for B 12 malabsorption and gastric cancer in H. pylori infected individuals. This may be more important in patients from non-industialized countries and Asia where there (continued on page 48) 46
5 (continued from page 46) is a higher incidence of corpus predominant type of H. pylori infection. If this were to be the case, then one may anticipate an increased prevalence of GERD and its complications of Barrett s esophagus and adenocarcinoma of the esophagus and gastric cardia in the developing countries of the world during the next few decades associated with a decreased prevalence of H. pylori infection and incidence of gastric cancer of the body and antrum. This is an evolving area with important implications for both individual patients as well as for the nations of the world. References 1. Howard PJ, Heading RC. Epidemiology of gastroesophageal reflux disease. World J Surg, 1992:16: Graham DY. Helicobactor pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology, 1997;113: Traub M. The spectrum of the symptoms and presentations of gastroesophageal reflux disease. Gastroenterol Clin North Am, 1990;19: Robertson D, Aldersley M, Shepherd H, et al. Patterns of acid reflux in complicated oesophagitis. Gut, 1987;28: Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux is a risk factor for esophageal carcinoma. N Engl J Med, 1999;340: Shaker R, Castell DO, Schoenfeld PS, et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol, 2003;98: Huang X, Zhu HM, Deng CZ, et al. Gastroesophageal reflux: the features in elderly patients. World J Gastroenterol, 1995;5(5): Chait MM. Gastroesophageal reflux disease in the elderly. Practical Gastroenterology, 2005;29:(5) Moss SF, Calam J. Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of H. pylori. Gut, 1993;34(7): Gutierrez O, Melo M, Segura AM, et al. Cure of Helicobactor pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol, 1997;32(7): Haruma K, Mihara M, Okamoto E, et al. Eradication of Helicobactor pylori increases gastric acidity in patients with atrophic gastritis of the corpus evaluation of 24 hour ph monitoring. Gut, 1999;13: Bercik P, Verdu E, Armstrong D, et al. The effects of ammonia on Omeprazole-induced reduction of gastric acidity in subjects with Helicobactor pylori infection. Am J Gastroenterol, 2000; 95: El-Omar EM, Penman ID, Ardill JE, et al. Helicobactor pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology, 1991;109: Kuipers EJ, Perez-Perez GI, Meuwissen SG, et al. Helicobactor pylori and atrophic gastritis: importance of the cag A status. J Natl Cancer Inst, 1995;87: Van Doorn LJ, Figueiredo C, Sanna R, et al. Clinical relevance of cag A, vac A, and ice A status of Helicobactor pylori. Gastroentertology, 1998;115: Tefera S, Hatlebakk JG, Berstad A. The effect of Helicobactor pylori eradication on gastro-oesophageal reflux. Aliment Pharmacol Ther, 1999;13: Wu JC, Lai AC, Wong SK, et al. Dysfunction of oesophageal motility in Helicobactor pylori infected patients with reflux oesophagitis. Aliment Pharmacol Ther, 2001;15: Labenz J, Blum AL Bayerdorffer E, et al. Curing Helicobactor pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology, 1997;112: Hamada H, Haruma K, Mihara M, et al. High incidence of relux esophagitis after eradication therapy for Helicobactor pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther, 2000;14: Take S, Mizuno M, Ishiki K, et al. The effect of eradicating Helicobactor pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol, 2005:100: Vakil N, Hahn B, McSorley. Recurrent symptoms and gastroesophageal reflux disease in patients with duodenal ulcer treated for Helicobactor pylori infection. Aliment Pharmacol Ther, 2000; 14: Fallone C, Barkun A, Friedman G, et al. Is Helicobactor pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol, 2000;95: Everhaart JE. Recent developments in the epidemiology of Helicobactor pylori. Gastroenterol Clin N Am, 2000;29: Labenz J, Jespersen D, Kulig M, et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol, 2004;99: Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobactor pylori infection in patients with reflux esophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomized controlled trial. Gut, 2004;53: Sharma P. Recent advances in Barrett s esophagus: short segment Barrett s esophagus and cardia intestinal metaplasia. Semin Gastroent Dis, 1999;10: Zhang J, Chen XL, Wang KM, et al. Relationship of gastric Helicobactor pylori infection to Barrett s esophagus and gastroesophageal reflux disease in Chinese. World J Gastroenterol, 2004;10: Ye W, Held M, Lagergren J, et al. Helicobactor pylori infection and gastric atrophy: risk of adenocarcinoma and squamous cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst, 2004;96: Labenz J, Tillenburg B, Peitz U, et al. Helicobacter augments the ph-increaseing effect of omeprazole in patients with duodenal ulcer. Gastroenterology, 1996;110: Wu JCY, Chan FKL, Ching JYL, et al. Effect of Helicobactor pylori on the treatment of gastroesophageal reflux disease: a doubleblind, placebo-controlled, randomized trial. Gut, 2004;53: Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter infection accelerates healing of reflux esophagitis during treatment with the proton inhibitor pantoprazole. Gastroenterology, 1999; 117: Gillen D, Wirz AA, Neithercut WD, et al. Helicobactor pylori potentiates the inhibition of gastric acid secretion by omeprazole. Gut, 1999;44: Kuipers EJ, Uyterlinde AM, Penna AS, et al. Increase of Helicobactor pylori-associated corpus gastritis during acid suppressive therapy: implications for long term safety. Am J Gastroenterol, 1995;90: Sachs G. Gastritis, Helicobactor pylori, and proton pump inhibitors. Gastroenterology, 1997;112: Malfertheiner P, Megraud F, O Morain C. Current European concepts in the management of Helicobactor pylori infection. The Maastricht consensus report. Gut, 1997;41: Kuipers EJ, Lundell L, Klinkenberg EC, et al. Atrophic gastritis and Helicobacter infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med, 1996;334:
Esophageal Adenocarcinoma Developing after Eradication of Helicobacter pylori
355 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the
More informationSafety Of. long-term PPI. Layli Eslami, MD Tehran, 1393
Safety Of long-term PPI Layli Eslami, MD Tehran, 1393 n The introduction of PPIs in the late 1980s optimized the medical treatment of acidrelated disorders n In some cases such as GERD patients given the
More informationDisclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome
Gastrointestinal Motility Disorders & Irritable Bowel Syndrome None Disclosures Jasmine Zia, MD Acting Assistant Professor Division of Gastroenterology, University of Washington 6 th Asian Health Symposium
More informationFrequency of Barrett Esophagus in Patients with Symptoms of Gastroesophageal Reflux Disease
Original Article Frequency of Barrett Esophagus in Patients with Symptoms of Gastroesophageal Reflux Disease From Military Hospital, Rawalpindi Obaid Ullah Khan, Abdul Rasheed Correspondence: Dr. Abdul
More informationGERD: 2014 Dilemmas and Solutions. Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University
GERD: 2014 Dilemmas and Solutions Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University How to Maximize Your PPI Treatment? Improve compliance and adherance Fass R. Am J Gastroenterol.
More informationReview article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 10 15. Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors J. G. HATLEBAKK Department of Medicine, Haukeland Sykehus,
More informationReview article: pharmacology of esomeprazole and comparisons with omeprazole
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 5 9. Review article: pharmacology of esomeprazole and comparisons with omeprazole J. DENT Department of Gastroenterology, Hepatology and General Medicine, Royal
More informationHelicobacter pylori Eradication Does Not Exacerbate Reflux Symptoms in Gastroesophageal Reflux Disease
GASTROENTEROLOGY 2001;121:1120 1126 Helicobacter pylori Eradication Does Not Exacerbate Reflux Symptoms in Gastroesophageal Reflux Disease PAUL MOAYYEDI, CHANDU BARDHAN, LYNNE YOUNG, MICHAEL F. DIXON,
More informationUnmet Needs in the Management of Gastroesophageal Reflux Disease
Unmet Needs in the Management of Gastroesophageal Reflux Disease Ronnie Fass MD Professor of Medicine Case Western Reserve University Chairman, Division of Gastroenterology and Hepatology Director, Esophageal
More informationCorpus gastritis is protective against reflux oesophagitis
Gut 1999;45:181 185 181 Corpus is protective against reflux H B El-Serag, A Sonnenberg, M M Jamal, J M Inadomi, L A Crooks, R M Feddersen Department of Veterans AVairs Medical Centre, University of New
More informationGastroesophageal reflux disease (GERD) is the. Gastroesophageal Reflux Disease in the Elderly A SPECIAL ARTICLE INTRODUCTION PATHOGENESIS
Gastroesophageal Reflux Disease in the Elderly Maxwell Chait Gastroesophageal reflux disease (GERD) is the most common upper gastrointestinal problem seen in adults. Although the elderly have fewer complaints
More informationSASKATCHEWAN REGISTERED NURSES ASSOCIATION
DEFINITION Reflux of gastric contents into the esophagus, which results in esophageal irritation or inflammation. IMMEDIATE CONSULTATION REQUIRED IN THE FOLLOWING SITUATIONS Dysphagia (solid food, progressive)
More informationGERD DIAGNOSIS & TREATMENT DISCLOSURES 4/18/2018
GERD DIAGNOSIS & TREATMENT Subhash Chandra MBBS Assistant Professor CHI Health Clinic Gastroenterology Creighton University, School of Medicine April 28, 2018 DISCLOSURES None 1 OBJECTIVES Review update
More informationDisclosures. Proton Pump Inhibitors Deprescribing? Deprescribing PPI Objectives. Deprescribing. Proton Pump Inhibitors (PPI) 5/28/2018.
Proton Pump Inhibitors Deprescribing? None Disclosures Chad Burski, MD Assistant Professor of Medicine UAB Gastroenterology Deprescribing PPI Objectives AR Why? Who? How? The mechanism of action of Proton
More informationCharacteristics of patients with erosive and nonerosive GERD in high-helicobacter-pylori prevalence region
Diseases of the Esophagus (2004) 17, 223 227 2004 ISDE Blackwell Publishing, Ltd. Original article Characteristics of patients with erosive and nonerosive GERD in high-helicobacter-pylori prevalence region
More informationIntragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized, two-way crossover study
Aliment Pharmacol Ther 2005; 21: 963 967. doi: 10.1111/j.1365-2036.2005.02432.x Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized,
More informationEffect of Helicobacter pylori infection and its eradication on nutrition
Aliment Pharmacol Ther 2002; 16: 799 806. Effect of Helicobacter pylori infection and its eradication on nutrition T. FURUTA*, N. SHIRAI*, F. XIAO*, M. TAKASHIMA* & H. HANAI *First Department of Medicine
More informationEsophageal Disorders. Learning Objectives. Introduction. Gastroesophageal Reflux Disease. Reza Shaker, MD, and Benson T.
Esophageal Disorders Reza Shaker, MD, and Benson T. Massey, MD, FACP Learning Objectives AFTER COMPLETING THIS CHAPTER, THE LEARNER SHOULD BE ABLE TO: 1. Recognize the typical and atypical presentations
More informationGASTROESOPHAGEAL REFLUX DISEASE. William M. Brady
Drugs of Today 1998, 34(1): 25-30 Copyright PROUS SCIENCE GASTROESOPHAGEAL REFLUX DISEASE William M. Brady Section of General Internal Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania,
More informationH elicobacter pylori is a human pathogen that causes
1543 STOMACH Effect of Helicobacter pylori eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects D Vaira, N Vakil, M Rugge, L Gatta, C Ricci, M Menegatti, G Leandro,
More information1. Introduction. Correspondence should be addressed to Wei-Chen Tai; Received 29 May 2013; Accepted 5 July 2013
Gastroenterology Research and Practice Volume 2013, Article ID 480325, 6 pages http://dx.doi.org/10.1155/2013/480325 Clinical Study The Frequencies of Gastroesophageal and Extragastroesophageal Symptoms
More informationPutting Chronic Heartburn On Ice
Putting Chronic Heartburn On Ice Over the years, gastroesophageal reflux disease has proven to be one of the most common complaints facing family physicians. With quicker diagnosis, this pesky ailment
More informationGI Pharmacology. Dr. Alia Shatanawi 5/4/2018
GI Pharmacology Dr. Alia Shatanawi 5/4/2018 Drugs Used in Gastrointestinal Diseases Drugs used in Peptic Ulcer Diseases. Drugs Stimulating Gastrointestinal Motility &Laxatives. Antidiarrheal Agents. Drugs
More informationIncreased gastric acid secretion after Helicobacter pylori eradication may be a factor for developing re ux oesophagitis
Aliment Pharmacol Ther 2001; 15: 813±820. Increased gastric acid secretion after Helicobacter pylori eradication may be a factor for developing re ux oesophagitis T. KOIKE, S. OHARA, H. SEKINE, K. IIJIMA,
More informationAssessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer
618 University Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, UK K E L McColl A El-Nujumi L S Murray E M El-Omar A Dickson A W Kelman T E Hilditch Correspondence to: Professor
More informationACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease
ACG Clinical Guideline: Diagnosis and Management of Gastroesophageal Reflux Disease Philip O. Katz MD 1, Lauren B. Gerson MD, MSc 2 and Marcelo F. Vela MD, MSCR 3 1 Division of Gastroenterology, Einstein
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationBarrett s Esophagus: Old Dog, New Tricks
Barrett s Esophagus: Old Dog, New Tricks Stuart Jon Spechler, M.D. Chief, Division of Gastroenterology, VA North Texas Healthcare System; Co-Director, Esophageal Diseases Center, Professor of Medicine,
More informationHelicobacter pylori: Diagnosis, treatment and risks of untreated infection
Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb
More informationFunctional Dyspepsia. Norbert Welkovics Heine van der Walt
Norbert Welkovics Heine van der Walt Characteristics: Central abdomen Pain or discomfort Not associated with bowel movements No structural or biochemical abnormalty Definition Part of Gastroduodenal disorders
More informationBurning Issues in Gastroesophageal Reflux Disease (GERD)
3:45 4:45pm Burning Issues in GERD SPEAKER Prateek Sharma, MD, FACG, FACP Presenter Disclosure Information The following relationships exist related to this presentation: Prateek Sharma, MD, FACG, FACP,
More informationGastroesophageal Reflux Disease, Paraesophageal Hernias &
530.81 553.3 & 530.00 43289, 43659 1043432842, MD Assistant Clinical Professor of Surgery, UH JABSOM Associate General Surgery Program Director Director of Minimally Invasive & Bariatric Surgery Programs
More informationPrompt Upper Endoscopy Is an Appropriate Initial Management in Uninvestigated Chinese Patients With Typical Reflux Symptoms
nature publishing group ORIGINAL CONTRIBUTIONS 1947 Prompt Upper Endoscopy Is an Appropriate Initial Management in Uninvestigated Chinese Patients With Typical Reflux Symptoms Sui Peng, MD 1, Li-Shou Xiong,
More informationEffect of Helicobacter pylori Eradication on Reflux Esophagitis Therapy: A Multi center Randomized Control Study
Original Article Effect of Helicobacter pylori Eradication on Reflux Esophagitis Therapy: A Multi center Randomized Control Study Yan Xue 1, Li Ya Zhou 1, San Ren Lin 1, Xiao Hua Hou 2, Zhao Shen Li 3,
More informationAchalasia is a rare disease with an annual incidence estimated REVIEWS. Erroneous Diagnosis of Gastroesophageal Reflux Disease in Achalasia
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:1020 1024 REVIEWS Erroneous Diagnosis of Gastroesophageal Reflux Disease in Achalasia BOUDEWIJN F. KESSING, ALBERT J. BREDENOORD, and ANDRÉ J. P. M. SMOUT
More informationObesity Is Associated With Increased Transient Lower Esophageal Sphincter Relaxation. Introduction. Predisposing factor. Introduction.
Obesity Is Associated With Increased Transient Lower Esophageal Sphincter Relaxation Gastro Esophageal Reflux Disease (GERD) JUSTIN CHE-YUEN WU, et. al. The Chinese University of Hong Kong Gastroenterology,
More informationOriginal Article. Helicobacter pylori eradication and histopathological esophagitis in dyspeptic patients
Tropical Gastroenterology 2010;31(3):175 179 Original Article Helicobacter pylori eradication and histopathological esophagitis in dyspeptic patients Mohsen Amini 1, Ashraf Karbasi 1, Hossein Khedmat 1,
More informationRefractory GERD. Kenneth R. DeVault, MD, FACG President American College of Gastroenterology Chair Department of Medicine Mayo Clinic Florida
Refractory GERD Kenneth R. DeVault, MD, FACG President American College of Gastroenterology Chair Department of Medicine Mayo Clinic Florida Objectives Define the terminology associated with refractory
More informationThe usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.
Name Gasec - 2 Gastrocaps Composition Gasec-20 Gastrocaps Each Gastrocaps contains: Omeprazole 20 mg (in the form of enteric-coated pellets) Properties, effects Proton Pump Inhibitor Omeprazole belongs
More informationRpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives
Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment
More informationGastro esophageal reflux disease DR. AMMAR I. ABDUL-LATIF
Gastro esophageal reflux disease )GERD( DR. AMMAR I. ABDUL-LATIF GERD DEFINITION EPIDEMIOLOGY CAUSES PATHOGENESIS SIGNS &SYMPTOMS COMPLICATIONS DIAGNOSIS TREATMENT Definition Montreal consensus defined
More informationThe Impact of Gender on the Symptom Presentation and Life Quality of Patients with Erosive Esophagitis and Non-Erosive Reflux Disease
ARC Journal of Hepatology and Gastroenterology Volume 1, Issue 1, 2016, PP 3-8 www.arcjournals.org The Impact of Gender on the Symptom Presentation and Life Quality of Patients with Erosive Esophagitis
More informationESOPHAGEAL CANCER AND GERD. Prof Salman Guraya FRCS, Masters MedEd
ESOPHAGEAL CANCER AND GERD Prof Salman Guraya FRCS, Masters MedEd Learning objectives Esophagus anatomy and physiology Esophageal cancer Causes, presentations of esophageal cancer Diagnosis and management
More informationBarrett s Esophagus. Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI
Barrett s Esophagus Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI A 58 year-old, obese white man has had heartburn for more than 20 years. He read a magazine
More informationModule 2 Heartburn Glossary
Absorption Antacids Antibiotic Module 2 Heartburn Glossary Barrett s oesophagus Bloating Body mass index Burping Chief cells Colon Digestion Endoscopy Enteroendocrine cells Epiglottis Epithelium Absorption
More informationMaastricht Ⅴ /Florence
2016 21 10 577 Maastricht Ⅴ /Florence 200001 2015 10 8 9 Maastricht V 1 / 2 3 4 / 5 Maastricht Ⅴ Interpretation of Management of Helicobacter pylori Infection the Maastricht Ⅴ / Florence Consensus Report
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/48400
More informationHigh Recurrence Rate of Idiopathic Peptic Ulcers in Long-Term Follow-up
Gut and Liver, Vol. 7, No. 2, March 2013, pp. 175-181 ORiginal Article High Recurrence Rate of Idiopathic Peptic Ulcers in Long-Term Follow-up Hyuk Yoon, Sang Gyun Kim, Hyun Chae Jung, and In Sung Song
More informationFunctional dyspepsia: relationship between clinical subgroups and Helicobacter pylori status in Western Turkey
Brazilian Journal of Medical and Biological Research (2003) 36: 747-751 Dyspepsia and Helicobacter pylori ISSN 0100-879X 747 Functional dyspepsia: relationship between clinical subgroups and Helicobacter
More informationGERD: A linical Clinical Clinical Update Objectives
GERD: A Clinical Update Jeff Gilbert, M.D. University i of Kentucky Gastroenterology 11/6/08 Objectives To review the basic pathophysiology underlying gastroesophageal reflux disease To highlight current
More informationAcid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe
Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs 1 Division of Gastroenterology UC San Diego School of Medicine Clinical presentations of Helicobacter pylori infection
More informationEosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis (EoE) 01.06.2016 EoE: immune-mediated disorder food or environmental antigens => Th2 inflammatory response. Key cytokines: IL-4, IL-5, and IL-13 stimulate the production of eotaxin-3
More informationA model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?
Alimentary Pharmacology and Therapeutics A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing? P. O. Katz*, D. A. Johnson
More informationHistory. Prevalence at Endoscopy. Prevalence and Reflux Sx. Prevalence at Endoscopy. Barrett s Esophagus: Controversy and Management
Barrett s Esophagus: Controversy and Management History Norman Barrett (1950) Chronic Peptic Ulcer of the Oesophagus and Oesophagitis Allison and Johnstone (1953) The Oesophagus Lined with Gastric Mucous
More informationPEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School
PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease
More informationDisclosures. Heartburn and Barrett s Esophagus. Heartburn and Barrett s Esophagus. GERD is common in the U.S. None
Heartburn and Barrett s Esophagus None Disclosures Christian Mathy, MD University of California, San Francisco 2015 Heartburn and Barrett s Esophagus Heartburn and GERD GERD therapy Extraesophageal GERD
More informationHelicobacter pylori Improved Detection of Helicobacter pylori
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.4.2099 RESEARCH ARTICLE Improved Detection of Helicobacter pylori Infection and Premalignant Gastric Mucosa Using Conventional White Light Source Gastroscopy
More information34th Annual Toronto Thoracic Surgery Refresher Course
34th Annual Toronto Thoracic Surgery Refresher Course TREATMENT OPTIONS FOR ACHALASIA Dr. Carmine Simone Director, Intensive Care Unit Head, Division of Critical Care Departments of Medicine and Surgery
More informationKeywords: Helicobacter pylori; oesophagitis; gastro-oesophageal reflux disease; atrophic gastritis; gastric cancer
Gut 2001;49:335 340 335 Division of Gastroenterology, Department of Internal Medicine, University of Tokyo, Tokyo, Japan Y Yamaji M Okamoto H Yoshida T Kawabe Y Shiratori M Omata Department of Gastroenterology,
More informationTable 2.9. Case control studies of helicobacter pylori infection and oesophageal adenocarcinoma
Characteristics of Characteristics of controls Detection Chow et al (1998) 1993-1995 129 of newly diagnosed oesophageal/gastric cardia (OGC) adenocarcinoma. 224 population controls selected by random digit
More informationNew developments in pathogenesis, gastric cancer. Matthias Ebert. II. Medizinische Klinik Klinikum rechts der Isar TU München
New developments in pathogenesis, diagnosis, therapy and prevention of gastric cancer Matthias Ebert II. Medizinische Klinik Klinikum rechts der Isar TU München Gastric Cancer Pathogenesis Diagnosis Treatment
More informationHelicobacter pylori and Gastroesophageal Reflux Disease
CHAPTER 16 Helicobacter pylori and Gastroesophageal Reflux Disease Maria Pina Dore 1 and David Y. Graham 2 ' Jnstituto di CLinica Medica, University of Sassari, Italy, and Michael E. DeBakey VA Medical
More informationSystematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease where next?
Aliment Pharmacol Ther 2005; 22: 79 94. doi: 10.1111/j.1365-2036.2005.02531.x Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease where next? R. FASS, M. SHAPIRO, R. DEKEL
More informationMyogenic Control. Esophageal Motility. Enteric Nervous System. Alimentary Tract Motility. Determinants of GI Tract Motility.
Myogenic Control Esophageal Motility David Markowitz, MD Columbia University, College of Physicians and Surgeons Basic Electrical Rythym: intrinsic rhythmic fluctuation of smooth muscle membrane potential
More informationEsophageal Motility. Alimentary Tract Motility
Esophageal Motility David Markowitz, MD Columbia University, College of Physicians and Surgeons Alimentary Tract Motility Propulsion Movement of food and endogenous secretions Mixing Allows for greater
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Achalasia, barium esophagography for, 57 58 Acid pocket, 18 19 Acid-sensing ion, 20 Acupuncture, 128 Adiponectin, in obesity, 166 ADX10059 metabotropic
More informationCLINICAL CHARACTERISTICS, ENDOSCOPIC IMAGE OF GASTROESOPHAGEAL REFLUX DISEASE IN THE ELDERLY
CLINICAL CHARACTERISTICS, ENDOSCOPIC IMAGE OF GASTROESOPHAGEAL REFLUX DISEASE IN THE ELDERLY Ho Thi Kim Thanh, Vu Thi Kim Ngoc Hanoi Medical University, National Geriatric Hospital This study aimed to
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationSymptoms suggestive of gastroesophageal reflux disease. Gastroesophageal Reflux Among Different Racial Groups in the United States
GASTROENTEROLOGY 2004;126:1692 1699 Gastroesophageal Reflux Among Different Racial Groups in the United States HASHEM B. EL SERAG,*, NANCY J. PETERSEN, JUNAIA CARTER, DAVID Y. GRAHAM,* PETER RICHARDSON,
More informationSUMMARY INTRODUCTION. Accepted for publication 8 July 2004
Aliment Pharmacol Ther 2004; 20: 733 744. doi: 10.1111/j.1365-2036.2004.02172.x Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients
More informationMEDICAL POLICY SUBJECT: MAGNETIC ESOPHAGEAL RING/ MAGNETIC SPHINCTER AUGMENTATION FOR THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD)
MEDICAL POLICY SUBJECT: MAGNETIC ESOPHAGEAL RING/ MAGNETIC SPHINCTER PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial
More informationDavid Markowitz, MD. Physicians and Surgeons
Esophageal Motility David Markowitz, MD Columbia University, College of Columbia University, College of Physicians and Surgeons Alimentary Tract Motility Propulsion Movement of food and endogenous secretions
More informationCommittee Approval Date: October 14, 2014 Next Review Date: October 2015
Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next
More informationGastrointestinal pathology 2018 lecture 4. Dr Heyam Awad FRCPath
Gastrointestinal pathology 2018 lecture 4 Dr Heyam Awad FRCPath Topics to be covered Peptic ulcer disease Hiatal hernia Gastric neoplasms Peptic ulcer disease (PUD)= chronic gastric ulcer Causes H pylori
More informationNexium 24HR. Tools and information for you and your pharmacy team NOW OTC FOR FREQUENT HEARTBURN. Consumer Healthcare Pfizer Inc.
NOW OTC FOR FREQUENT HEARTBURN w e N Nexium 24HR P H A R M A S S I S T K I T Tools and information for you and your pharmacy team 2014 Pfizer Inc. NXM041468 05/14 Q: What is the indication for Nexium 24HR
More informationPatients with established gastro-esophageal reflux disease might benefit from Helicobacter pylori eradication
ORIGINAL ARTICLE Annals of Gastroenterology (2014) 27, 352-356 Patients with established gastro-esophageal reflux disease might benefit from Helicobacter pylori eradication John M. Moschos a, George Kouklakis
More informationNew Developments in the Endoscopic Diagnosis and Management of Barrett s Esophagus
New Developments in the Endoscopic Diagnosis and Management of Barrett s Esophagus Prateek Sharma, MD Key Clinical Management Points: Endoscopic recognition of a columnar lined distal esophagus is crucial
More informationThe Risk Factors and Quality of Life in Patients with Overlapping Functional Dyspepsia or Peptic Ulcer Disease with Gastroesophageal Reflux Disease
Gut and Liver, Vol. 8, No. 2, March 2014, pp. 160-164 ORiginal Article The Risk Factors and Quality of Life in Patients with Overlapping Functional Dyspepsia or Peptic Ulcer Disease with Gastroesophageal
More informationPPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI)
Outline Quick basics on Proton Pump Inhibitors (PPIs) PPIs: Good or Bad? What are potential risks of PPI therapy? How to approach your patients American Gastroenterology Association (AGA) recommendations
More informationThe interactions between Helicobacter pylori, acid, and
GASTROENTEROLOGY 1999;116:479 492 EDITORIALS Helicobacter pylori, Acid, and Omeprazole Revisited: Bacterial Eradication and Rebound Hypersecretion See articles on pages 239 and 248. The interactions between
More informationDrug Class Review on Proton Pump Inhibitors
Drug Class Review on Proton Pump Inhibitors Final Report Update 4 July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May
More informationFecal incontinence causes 196 epidemiology 8 treatment 196
Subject Index Achalasia course 93 differential diagnosis 93 esophageal dysphagia 92 95 etiology 92, 93 treatment 93 95 work-up 93 Aminosalicylates, pharmacokinetics and aging effects 36 Antibiotics diarrhea
More informationPeptic ulcer disease Disorders of the esophagus
Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth
More informationRefractory GERD : case presentation and discussion
Refractory GERD : case presentation and discussion Ping-Huei Tseng National Taiwan University Hospital May 19, 2018 How effective is PPI based on EGD? With GERD symptom 75% erosive 25% NERD Endoscopy 81%
More informationTBURN TBURN BURN ARTBURN EARTBURN EART HEARTBURN: HOW TO GET IT OFF YOUR CHEST
TBURN BURN TBURN ARTBURN. EARTBURN EART N EARTBURN HEARTBURN: HOW TO GET IT OFF YOUR CHEST Do you sometimes wake up at night with a sharp, burning sensation in your chest? Does this sometimes happen during
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationMucosal breaks show same circumferential distribution in majority of patients with recurrent reflux esophagitis
Original article Mucosal breaks show same circumferential distribution in majority of patients with recurrent reflux esophagitis Authors Naoki Fukuda 1,, Norihisa Ishimura 1,MayumiOkada 1,Daisuke Izumi
More informationGastric juice acidity in upper gastrointestinal diseases
Online Submissions: http://www.wjgnet.com/1007-9327office wjg@wjgnet.com doi:10.3748/wjg.v16.i43.5496 World J Gastroenterol 2010 November 21; 16(43): 5496-5501 ISSN 1007-9327 (print) ISSN 2219-2840 (online)
More informationS. Sandberg-Lewis, ND, DHANP
Functional Gastroenterology Webinar One 6-28-13 S. Sandberg-Lewis, ND, DHANP Proton pump inhibitors- Effects on: secretion gastric mucosa food allergy bile reflux Barrett metaplasia and dysplasia esophageal
More informationRisk Factors for Helicobacter pylori Infection and Endoscopic Reflux Esophagitis in Healthy Young Japanese Volunteers
doi: 10.2169/internalmedicine.8669-16 Intern Med 56: 2979-2983, 2017 http://internmed.jp ORIGINAL ARTICLE Risk Factors for Helicobacter pylori Infection and Endoscopic Reflux in Healthy Young Japanese
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationGI update. Common conditions and concerns my patients frequently asked about
GI update Common conditions and concerns my patients frequently asked about Specific conditions I ll try to cover today 1. Colon polyps, colorectal cancer and colonoscopy 2. Crohn s disease 3. Peptic ulcer
More informationCorrelation between gastric acid secretion and severity of acid reflux in children
The Turkish Journal of Pediatrics 2003; 45: 6-10 Original Correlation between gastric acid secretion and severity of acid reflux in children Nicolas Kalach 1-3, Abdul Monem Badran 1, Patrick Jaffray 2,
More informationNexium 24HR Pharmacy Training
Nexium 24HR Pharmacy Training Your pharmacist's advice is required. Always read the label. Use only as directed. If symptoms persist, consult your doctor/ healthcare professional. Pfizer Consumer Healthcare
More informationPage 1. Objectives. The Role of the Pharmacist as Gatekeeper to the Appropriate Use of OTC PPI Therapy in Frequent Heartburn
Page 1 The Role of the Pharmacist as Gatekeeper to the Appropriate Use of OTC PPI Therapy in The Role of the Pharmacist as Gatekeeper to the Appropriate Use of OTC PPI Therapy in Colin W. Howden, MD, FRCP
More informationEvolution of gastro-oesophageal reflux disease over 5 years under routine medical care the ProGERD study
Alimentary Pharmacology and Therapeutics Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care the ProGERD study P. Malfertheiner*, M. Nocon, M. Vieth à, M. Stolte, D.
More informationAlimentary Pharmacology & Therapeutics SUMMARY
Alimentary Pharmacology & Therapeutics Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayedrelease esomeprazole capsules on nocturnal
More informationMaximizing Outcome of Extraesophageal Reflux Disease. (GERD) is often accompanied
...PRESENTATIONS... Maximizing Outcome of Extraesophageal Reflux Disease Based on a presentation by Peter J. Kahrilas, MD Presentation Summary Gastroesophageal reflux disease (GERD) accompanied by regurgitation
More information